Riociguat ( BAY 63-2521; BAY63-2521; Riociguat )

Catalog No. M18919 CAS No. 625115-55-1

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Group Booking Get Quotation Bulk Inquiry Add to Cart

Product Name

Riociguat
Note

Research use only, not for human use.
Brief Description

Riociguat is a stimulator of guanylate cyclase which causes relaxation of vascular smooth muscle and is used to treat severe pulmonary arterial hypertension.
Description

Riociguat, also known as BAY 63-2521, is a novel drug that is currently in clinical development by Bayer. It is a stimulator of soluble guanylate cyclase (sGC). At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class of sGC stimulators.
Synonyms

BAY 63-2521; BAY63-2521; Riociguat
Pathway

Others
Target

Other Targets
Recptor

Guanylate cyclase
Research Area

Cardiovascular Disease
Indication

——

CAS Number

625115-55-1
Formula Weight

422.42
Molecular Formula

C20H19FN8O2
Purity

98%
Solubility

DMSO : ≥ 50 mg/mL; 118.37 mM
SMILES

C(=O)(N(C)c1c(nc(nc1N)c1c2c(nccc2)n(n1)Cc1c(cccc1)F)N)OC
Chemical Name

methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate

1. Schermuly RT, et al. Eur Respir J. 2008, 32(4), 881-891.

Calculator

molnova catalog